Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide Maintenance in SCLC
NCT02179528Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Time to Disease Progression up to 12 months. Status: unknown.
02
Drugs
etoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02179528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179528.